Elite Pharmaceuticals, Inc.

Elite reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million. Cash provided by operations was $10.1 million, versus $14.8 million in the June 2025 quarter, and cash on the balance sheet was $38.9 million, up from $29.8 million at the beginning of the year. R&D expense was $2 million, versus $1.7 million a year ago. Management did not give next-quarter revenue or EPS guidance; instead, it said performance should be viewed against the unusually strong June 2025 quarter and that the business is now in a steadier market state, with future growth expected from the pipeline, including Methadone, Ropinirole ER, an undisclosed anticonvulsant filing, an undisclosed anticoagulant, and Oxy ER subject to FDA issue resolution.

Nasrat Hakim’s tone was confident and explanatory, emphasizing that the year-over-year decline is not a sign of weakness but a normal comparison against an unusually strong launch quarter. He said market share has increased across major products over the last four quarters and that several products are now stable or improving, including Lisdex, Amphetamine IR, Amphetamine ER, and Naltrexone. He framed future growth around the pipeline, new launches, and potential strategic alternatives such as Nasdaq uplisting and M&A.

Carter Ward focused on the mechanics behind the quarter: revenue was $32.4 million, operating profit was $7.5 million, R&D was $2 million, and operating cash flow was $10.1 million. He said the June 2025 quarter was Elite’s best quarter ever because of the early, high-priced generic Vyvanse/Lisdex launch, and that the current quarter reflects a more stable pricing environment. He also highlighted cash of $38.9 million and working capital of $84.1 million, explaining that working capital fell because $17 million of warrant derivatives moved from long-term to current liabilities, not because of a cash deterioration; he said liquidity will be directed toward new products, product line growth, and facility improvements.

Analyst questions centered on the year-over-year revenue decline, higher COGS, customer concentration, warrant treatment, cash deployment, facility expansion, Nasdaq timing, tariffs, and the launch timeline for pipeline assets. Management said the biggest customer at 60% of revenue does not explain pricing changes, which they attributed to generic-market supply, demand, and competition, and said higher COGS reflect both higher volumes and Naltrexone mix. On Nasdaq, Hakim said the company is open to uplisting alone, via acquisition, or alongside a deal, and his best guess is that it will be either done or close by the February call. He also said the company is discussing warrant outcomes with the holder and expects resolution before April 2027.